Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multinational, three-arm, randomized, double-blind, placebo-controlled Phase 2b clinical study of NP-120 (Ifenprodil) for the treatment of refractory chronic cough

X
Trial Profile

A multinational, three-arm, randomized, double-blind, placebo-controlled Phase 2b clinical study of NP-120 (Ifenprodil) for the treatment of refractory chronic cough

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 02 Apr 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ifenprodil (Primary)
  • Indications Cough
  • Focus Therapeutic Use
  • Sponsors Algernon Pharmaceuticals; Seyltx
  • Most Recent Events

    • 26 Mar 2024 According to an Algernon Pharmaceuticals media release, Seyltx plans to initiate Phase 2b placebo-controlled chronic cough study in CY2024. Algernons clinical management team will be available to provide support, oversight, and management of the study.
    • 22 Nov 2023 According to an Algernon Pharmaceuticals media release, Algernons clinical management team will be available to provide support, oversight and management of the study.
    • 14 Jul 2023 According to an Algernon Pharmaceuticals media release, the Company intends to issue on July 21, 2023 to Maxim Group LLC 200,000 common shares at a issue price of CDN dollars 0.22,as initial compensation for entering into an engagement letter pursuant to which Maxim will provide financial advisory and investment banking services, and assist in identifying and evaluating potential M and A and strategic opportunities.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top